Literature DB >> 25228122

Brain targeted intranasal delivery of tramadol: comparative study of microemulsion and nanoemulsion.

Jigar Lalani1, Dipesh Baradia1, Riddhi Lalani1, Ambikanandan Misra1.   

Abstract

OBJECTIVE: The present investigation was aimed to develop and compare microemulsion and nanoemulsion for brain targeted intranasal delivery of tramadol to achieve maximum therapeutic efficacy in treatment of episodic and emergency pain.
METHODS: Tramadol microemulsion (TME) and tramadol nanoemulsion (TNE) were developed and evaluated for physical properties. Ex vivo diffusion and nasal toxicity of TME and TNE were assessed by using sheep nasal mucosa. Biodistribution, pharmacokinetic and pharmacodynamic studies in mice were also performed.
RESULTS: Globule sizes of TME and TNE were 16.69 ± 3.21 and 136.3 ± 4.3 nm, respectively. TNE was found be safe with respect to multiple dosing via nasal route. Both TME and TNE were stable during accelerated stability studies. AUC(0→24) in mice brain for TME and TNE was significantly higher as compared with tramadol solution. TME and TNE displayed significantly higher antinociceptive effect for a period of 16 h as compared with tramadol solution. DISCUSSION: TME and TNE were delivered to brain, circumventing BBB in brisk manner, establishing immediately the minimum effective concentration required for therapeutic response. Significant enhancement in antinociceptive effect was observed after intranasal delivery of TME and TNE.
CONCLUSION: Intranasal administration of TME and TNE would be effective in management of episodic and emergency pain treatment.

Entities:  

Keywords:  Brain targeting; intranasal; microemulsion; nanoemulsion; pharmacokinetic

Year:  2014        PMID: 25228122     DOI: 10.3109/10837450.2014.959177

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  8 in total

Review 1.  Analgesia for Sheep in Commercial Production: Where to Next?

Authors:  Alison Small; Andrew David Fisher; Caroline Lee; Ian Colditz
Journal:  Animals (Basel)       Date:  2021-04-14       Impact factor: 2.752

2.  Rationally designed nanocarriers for intranasaltherapy of allergic rhinitis: influence of carrier type on in vivo nasal deposition.

Authors:  Marwa Ahmed Sallam; Hala Mahmoud Helal; Sana Mohamed Mortada
Journal:  Int J Nanomedicine       Date:  2016-05-25

Review 3.  Microemulsion-Based Media in Nose-to-Brain Drug Delivery.

Authors:  Anna Froelich; Tomasz Osmałek; Barbara Jadach; Vinam Puri; Bozena Michniak-Kohn
Journal:  Pharmaceutics       Date:  2021-02-02       Impact factor: 6.321

4.  Efficient Treatment of Experimental Cerebral Malaria by an Artemisone-SMEDDS System: Impact of Application Route and Dosing Frequency.

Authors:  Karsten Mäder; Jacob Golenser; Johanna Zech; Nadeen Salaymeh; Nicholas H Hunt
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

5.  Temozolomide hexadecyl ester targeted plga nanoparticles for drug-resistant glioblastoma therapy via intranasal administration.

Authors:  Siqi Wang; Yawen Yu; Aiping Wang; Xinliu Duan; Yuchen Sun; Liangxiao Wang; Liuxiang Chu; Yanan Lv; Nan Cui; Xuesong Fan; Chunjie Sha; Lixiao Xu; Kaoxiang Sun
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

6.  Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects.

Authors:  Xiuju Yan; Lixiao Xu; Chenchen Bi; Dongyu Duan; Liuxiang Chu; Xin Yu; Zimei Wu; Aiping Wang; Kaoxiang Sun
Journal:  Int J Nanomedicine       Date:  2018-01-09

Review 7.  Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections.

Authors:  Brenda Kischkel; Suélen A Rossi; Samuel R Santos; Joshua D Nosanchuk; Luiz R Travassos; Carlos P Taborda
Journal:  Front Cell Infect Microbiol       Date:  2020-09-03       Impact factor: 5.293

Review 8.  Strategies to Improve Drug Strength in Nasal Preparations for Brain Delivery of Low Aqueous Solubility Drugs.

Authors:  Patrícia C Pires; Márcio Rodrigues; Gilberto Alves; Adriana O Santos
Journal:  Pharmaceutics       Date:  2022-03-08       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.